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Abstract
Background: The Hedgehog (HH) pathway promotes tumorigenesis in a diversity of cancers.
Activation of the HH signaling pathway is caused by overexpression of HH ligands or mutations in
the components of the HH/GLI1 cascade, which lead to increased transactivation of GLI
transcription factors. Although negative kinase regulators that antagonize the activity of GLI
transcription factors have been reported, including GSK3β, PKA and CK1s, little is known
regarding positive kinase regulators that are suitable for use on cancer therapeutic targets. The
present study attempted to identify kinases whose silencing inhibits HH/GLI signalling in non-small
cell lung cancer (NSCLC).
Results: To find positive kinase regulators in the HH pathway, kinome-wide siRNA screening was
performed in a NSCLC cell line, A549, harboring the GLI regulatory reporter gene. This showed
that p70S6K2-silencing remarkably reduced GLI reporter gene activity. The decrease in the activity
of the HH pathway caused by p70S6K2-inhibition was accompanied by significant reduction in cell
viability. We next investigated the mechanism for p70S6K2-mediated inhibition of GLI1
transcription by hypothesizing that GSK3β, a negative regulator of the HH pathway, is activated
upon p70S6K2-silencing. We found that phosphorylated-GSK3β (Ser9) was reduced by p70S6K2-
silencing, causing a decreased level of GLI1 protein. Finally, to further confirm the involvement of
p70S6K2 in GLI1 signaling, down-regulation in GLI-mediated transcription by PI3KCA-inhibition
was confirmed, establishing the pivotal role of the PI3K/p70S6K2 pathway in GLI1 cascade
regulation.
Conclusion: We report herein that inhibition of p70S6K2, known as a downstream effector of
the PI3K pathway, remarkably decreases GLI-mediated transactivation in NSCLC by reducing
phosphorylated-GSK3β followed by GLI1 degradation. These results infer that p70S6K2 is a
potential therapeutic target for NSCLC with hyperactivated HH/GLI pathway.
Background
The Hedgehog (HH) signaling pathway is essential for the
control of multiple cell proliferation processes such as
pattern formation, stem cell maintenance and tumorigen-
esis [1,2]. Activation of HH signaling is initiated by the
HH ligand binding to its receptor, Patched (PTCH), lead-
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ing to relief of PTCH mediated repression of a G protein-
coupled receptor, Smoothened (SMOH) [3]. This event is
followed by the accumulation of unphosphorylated GLI
transcription factors at multiple amino acid residues [4].
The hypophosphorylation of GLI causes its stabilization,
which facilitates the transactivation of GLI regulatory
genes involved in cell cycle progression and apoptosis
inhibition such as Cyclin D1 [5], γ-catenin [6], and self-
induction of GLI1 [7]. The eventual transactivation/trans-
suppression of a number of genes by GLI transcription fac-
tors is of significance for exertion of the HH signaling
cascade's functions in normal-cell development or tumor-
igenesis. The regulation of HH signaling is controlled by
the conserved negative kinase regulators, protein kinase A
(PKA), casein kinases (CK1a and CK1e) and glycogen syn-
thase kinase 3β (GSK3β) which cooperatively phosphor-
ylate and inactivate GLI factors [8-10]. Up-regulation of
PTCH expression by HH signaling is also an important
feature of negative feedback [7]. Positive regulation is con-
trolled by the feedback loop of GLI transcription factors
which directly induce expression via binding to their pro-
moters [7]. Although the mechanism for coordinated reg-
ulation of GLI mediated transcription by HH ligands and
downstream positive and negative effectors has been pro-
gressively investigated, further analysis to decipher the
components involved in the HH cascade is eagerly antici-
pated.
Along with the multiple cellular processes and functions
known to be derived from HH cascade activation, recent
findings showing that the HH pathway plays a pivotal role
in stem cell maintenance have attracted great attention,
especially in the field of cancer research as a new potential
therapeutic target pathway for the treatment of various
types of cancers [5,11,12]. The aberrant up-regulation of
the HH pathway in tumorigenesis was first reported in
basal cell carcinomas resulting from either loss-of-func-
tion mutation in PTCH [13,14] or gain-of-function muta-
tion in SMOH [15]. The mutations or deregulated
expression in PTCH and SMOH have been subsequently
reported in various studies of brain, skin and muscle can-
cers [16,17], which are now categorized as ligand-inde-
pendent HH cascade-activated cancers. Recently, a subset
of non-small cell lung cancer (NSCLC) was found to be
hyperactive in the HH/GLI pathway independent of the
ligands by expressing high level of GLI1 protein [18]. The
other type of cancer in which the HH pathway is up-regu-
lated is ligand-dependent cancer, including prostate can-
cer [19], breast cancer [20], pancreatic carcinoma [21],
and small cell lung carcinoma [22]. The evidence pro-
vided in these studies that the HH pathway is activated in
a wide range of cancers suggests the importance of identi-
fication of effective therapeutic targets to interfere with the
HH pathway [23]. For ligand independent cancers there is
a particularly urgent need to find effective targets to sup-
press the GLI cascade due to the ineffectiveness of SMOH
inhibitors and other modalities to inhibit upstream com-
ponents of the HH/GLI cascade [18].
p70S6K2 is a member of the ribosomal S6 kinase family
and is involved in protein synthesis and cell proliferation
[24,25]. Increased activity or overexpression of p70S6K1/
2 has been reported in several types of cancers [26-28].
p70S6K2 is known to mainly work downstream of the
phosphoinositide 3-kinase (PI3K) pathway [29,30]. Up-
regulation of PI3K signaling by the activating mutation in
PI3K; the inactivating mutation in phosphatase and
tensin homolog (PTEN); or, receptor tyrosine kinase
(RTK)s activation through mitogenic stimuli, results in an
increase in serine-threonine kinase AKT activity, which
leads to the inactivating phosphorylation of tuberin
(TSC), and the activation of mammalian target of rapamy-
cin (mTOR) [29,31]. The increased activity of mTOR
drives the subsequent activation of its effectors including
p70S6K1/2 and 4E-BP1 [27]. The phosphorylated and
activated forms of p70S6K2 and 4E-BP1 cooperatively
promote translational up-regulation of the proteins
needed for cell cycle promotion. The functional role of
p70S6K1/2 in the PI3K/mTOR cascade has been well
established in the vast majority of cancer and develop-
ment research [29-31], and the role of p70S6K inhibition
in suppressing PI3K pathway-activated cancers has been
extensively studied. However, the involvement of p70S6K
in the regulation of the HH signaling pathway has not
been analyzed.
In this study, a kinome-wide siRNA screen was performed
to identify kinases whose silencing inhibits HH/GLI sign-
aling in NSCLC. We found that p70S6K2-silencing by
siRNA decreases GLI regulatory transcription ability in
NSCLC through modulating GSK3β. This report provides
the first evidence that p70S6K2 positively regulates the
HH cascade and could serve as a therapeutic target in GLI1
cascade-activated NSCLC independent of HH ligands.
Results
Kinome small interfering RNA (siRNA) screening to find 
Hedgehog (HH) pathway regulatory kinases
It has previously been reported that the HH/GLI1 path-
way is activated in some portion of NSCLC cell lines and
primary lung tumors [18]. Expression of GLI1 transcrip-
tion factor, which is a surrogate index of HH/GLI1 activa-
tion level, was examined in a panel of NSCLC cells lines
to find a suitable cell line for a kinome-wide small inter-
fering RNA (siRNA) screen. Consistent with previous
studies, it was found that various levels of GLI1  were
expressed in the cell lines, indicating that the HH/GLI1
pathway plays a pivotal role in NSCLC cancer cell progres-
sion (Fig. 1A). Of the eight cell lines examined, four
showed activated HH/GLI1 pathways (A549, H522, PC13Molecular Cancer 2009, 8:44 http://www.molecular-cancer.com/content/8/1/44
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and H1915). Of these, A549 was chosen for the subse-
quent kinome-siRNA screen, as the status of cancer-
related pathways in A549 cells has been well character-
ized, and A549 cells are amenable to sufficient siRNA
transfection. GLI-regulatory β-lactamase reporter gene was
transferred to the A549 cells and stable cell lines constitu-
tively expressing the reporter gene were established
(A549-GLI). Examination of reporter activity after intro-
duction of GLI1-siRNA into the A549-GLI cells to confirm
that the GLI regulatory β-lactamase  reporter gene was
under the control of GLI1 transcription factor, showed
that reporter gene activity was reduced to 32% compared
with control-siRNA treated cells (Fig. 1B). The silencing of
GLI3, known to be a transcriptional repressor of GLI-reg-
ulatory target genes, did not affect β-lactamase activity,
indicating that the prominently over-expressed GLI1 in
A549 is a major regulator of the β-lactamase reporter gene.
This suggests that A549-GLI cells were well suited to the
kinome-wide siRNA screen to identify kinases that influ-
ence HH/GLI1 pathway-mediated transcription. To find
kinases that affect the GLI regulatory reporter gene, the
A549-GLI cells were transfected by lipofection method
with kinome-siRNAs comprising about 500 protein
kinases.  β-lactamase activity was measured 72 hr after
transfection to examine the inhibitory effect on the
reporter gene by each kinase (Fig. 1C). In the large scale
siRNA screen, GLI1-siRNA was also included as a positive
control, and about 70% inhibition of reporter activity was
constantly observed by the GLI1 disruption, demonstrat-
ing that accuracy/reproducibility of the assay were relia-
Kinome-wide siRNA screen to find HH pathway regulatory kinases in NSCLC A549 cells Figure 1
Kinome-wide siRNA screen to find HH pathway regulatory kinases in NSCLC A549 cells. A, Identification of GLI1 
cascade activated NSCLC cell lines. The mRNA expression level of GLI1 in the eight NSCLC cells was measured with quantita-
tive RT-PCR. Data were normalized to internal β-actin expression and are presented as the mean and SD of three independent 
experiments. B, Establishment of stable A549 cell lines harboring GLI regulatory β-lactamase reporter gene activity. The A549-
GLI cells were treated with siRNAs as a control, GLI1, GLI2, GLI3 or PLK1 to confirm that β-lactamase was under the control of 
GLI1 transcription factor. PLK1-siRNA was used as a negative control to confirm that cytotoxicity did not affect reporter activ-
ity. Data are the mean and SD of three independent experiments. C, Results of the kinome-wide siRNA screen composed of 
about 500 protein kinases. The GLI reporter activity was shown as a percentage normalized to control-siRNA treated cells. **, 
P ≤ 0.01, compared with control.
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ble. The result of the siRNA screen illustrated that 17
kinases out of 500 siRNAs reduced the GLI-mediated
reporter gene activity to less than 45%. As protein kinase
C delta (PRKCD) was previously reported to positively
regulate HH/GLI1 pathway [32], kinase siRNAs that
down-regulated the reporter activity more than the cutoff
value (45%), which was determined based on the reduc-
tion level for PRKCD-siRNA, were selected as promising
candidates as positive regulators for HH/GLI1 pathway.
Among the kinase siRNAs that were hit, p70S6K2
(RPS6KB2) significantly reduced GLI-mediated reporter
gene transcription activity to 38%. Although it is well rec-
ognized that inhibition of p70S6K2 down-regulates the
oncogenic PI3K pathway, the effect of p70K6K2 on the
activity of the HH pathway has not been reported. There-
fore, we focused on p70S6K2 in the subsequent confirma-
tion and validation studies.
Inhibition of p70S6K2 reduces GLI1 regulatory 
transcription
The confirmation studies verified the down-regulation of
GLI1 transcription by p70S6K2 inhibition. Treatment of
A549-GLI with a different sequence of p70S6K2-siRNA
from the one used in the large scale siRNA screen, fol-
lowed by recovery of RNA from the transfected cells 48-hr
after siRNA transfection, and measurement of the silenc-
ing level of p70S6K2 by quantitative reverse transcriptase-
polymerase chain reaction (RT-PCR) (Fig. 2A) showed
that p70S6K2 mRNA expression was reduced to 11% com-
pared with control-siRNA treated cells. This illustrates that
sufficient level of repression was achieved for p70S6K2.
p70S6K2-silencing by siRNA down-regulates GLI regulatory reporter gene Figure 2
p70S6K2-silencing by siRNA down-regulates GLI regulatory reporter gene. A, mRNA-silencing level of p70S6K2 by 
siRNA. mRNA expression levels of p70S6K2 in the control- or p70S6K2-siRNA treated cells were measured 48 hr after siRNA 
transfection by quantitative RT-PCR. B, Effect of p70S6K2-silencing on GLI reporter gene activity. GLI regulatory β-lactamase 
activity was measured 72 and 96 hr after siRNA transfection. The value was normalized to cell number. C, Effect of p70S6K2-
silencing on cell viability. Cell viability was measured 72 and 96 hr after siRNA transfection as described in the materials and 
methods. Data are the mean and SD of three independent experiments. **, P ≤ 0.01, compared with control.
A BC







Control p70S6K2
siRNAs
m
R
N
A
 
E
x
p
r
e
s
s
i
o
n
 
(
%
)







Control p70S6K2
siRNAs
G
L
I
R
e
p
o
r
t
e
r
 
A
c
t
i
v
i
t
y
 
(
%
)
	

	








Control p70S6K2
siRNAs
m
R
N
A
 
E
x
p
r
e
s
s
i
o
n
 
(
%
)







Control p70S6K2
siRNAs
G
L
I
R
e
p
o
r
t
e
r
 
A
c
t
i
v
i
t
y
 
(
%
)







Control p70S6K2
siRNAs
C
e
l
l
 
V
i
a
b
i
l
i
t
y
 
(
%
)







Control p70S6K2
siRNAs
C
e
l
l
 
V
i
a
b
i
l
i
t
y
 
(
%
)
	

	

A549 cells A549 cells A549 cells
H1915 cells H1915 cells H1915 cells
	

	

	

	

∗∗
∗∗ ∗∗
∗∗
∗∗
∗∗
∗∗ ∗∗
∗∗
∗∗Molecular Cancer 2009, 8:44 http://www.molecular-cancer.com/content/8/1/44
Page 5 of 10
(page number not for citation purposes)
Similar to the large scale siRNA screen, 69% reduction in
GLI regulatory reporter gene activity was observed at 72
and 96 hr after transfection (Fig. 2B), which was equiva-
lent to the reduction level achieved by GLI1-siRNA. Meas-
urement of cell viability after p70S6K2  inhibition by
quantifying ATP level as an index of metabolically vital
cells allowed examination of whether proliferation of
A549 cells was dependent on the GLI1 pathway. A reduc-
tion in cell viability of about 50% and 70% was observed
72 and 96 hr respectively after transfection (Fig. 2C).
Reduction in both GLI reporter gene activity and cell via-
bility by p70S6K2-silencing was also confirmed in H1915
cells that stably expressed GLI regulatory β-lactamase gene
(Fig. 2A–2C bottom panels). In addition to the GLI regu-
latory  β-lactamase  reporter gene, expressions of endog-
enous GLI1 regulatory genes were quantified by RT-PCR.
Cyclin D1, part of G1/S cell cycle machinery, is known to
be mainly controlled by GLI1 and GLI2 in HH pathway
activated cells [5]. The expression of γ-catenin, which is
involved in apoptosis, is repressed by GLI1 transcription
factor [6]. Both cyclin D1 and γ-catenin were significantly
down- or up-regulated respectively by the increasing con-
centration of p70S6K2-siRNA (Fig. 3A and 3B). The
expression changes caused by the inhibition of p70S6K2
were similar to those caused by GLI1  inhibition: 50%
reduction of Cyclin D1 and 1.7-fold induction of γ-catenin.
p70S6K2-silencing degrades GLI1 transcription via 
activating GSK3β
GSK3β phosphorylates GLI and negatively modulates its
activity, leading to the destabilization of the transcription
factor. p70S6Ks down-regulates the activity of GSK3β by
phosphorylating Ser9 residue [33]. It was hypothesized
that the mechanism underlying the p70S6K2 inhibition-
mediated down-regulation of GLI1 transcription activity
is through the activation of GSK3β which leads to GLI
destabilization/inactivation. To examine this hypothesis,
phosphorylation levels of GSK3β at Ser9 residue after
p70S6K2-silencing by siRNA in A549 cells were measured.
Through western blotting, it was observed that p70S6K2
levels were remarkably reduced (Fig. 4A), which was in
accordance with mRNA expression levels shown previ-
ously. Although the phosphorylated form of GSK3β
(Ser9) was not affected by control-siRNA treatment, the
level of phospho-GSK3β was significantly reduced upon
the treatment of p70S6K2-siRNA in a time-dependent
manner (Fig. 4A). Total GSK3β was also unaltered by the
siRNA transfection. As GLI1 is stabilized by the inacti-
vated form of phosporylated-GSK3β, GLI1 protein level
was investigated by western blotting when p70S6K2 was
silenced. Upon the silencing of p70S6K2 by siRNA, signif-
icant reduction of GLI1 protein level was observed com-
pared with the control (Fig. 4B).
p70S6K2-silencing by siRNA decreases or increases expression of endogenous GLI1 regulatory genes Figure 3
p70S6K2-silencing by siRNA decreases or increases expression of endogenous GLI1 regulatory genes. A, Cyclin 
D1 mRNA expression level. B, γ-catenin mRNA expression level. mRNA expression levels of GLI1-regulatory genes were 
measured 48 hr after siRNA transfection by quantitative RT-PCR in A549 cells treated with GLI1-siRNA or p70S6K2-siRNA. 
Data were normalized to internal β-actin expression and are presented as the mean and SD of three independent experiments. 
*, P ≤ 0.05; **, P ≤ 0.01 compared with control.
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P70S6K2 is well recognized as a downstream effector of
the PI3K pathway [27,29], and no relationship between
p70S6K2 and the HH pathway has yet been reported.
Therefore, to further support the novel finding that
p70S6K2, as one of the components of the PI3K pathway,
modulates GLI1 transactivation ability, we examined
whether phosphatidylinositol 3-kinase catalytic alpha
polypeptide (PIK3CA) inhibition reduces GLI regulatory
reporter gene activity. In agreement with the p70S6K2
inhibition-mediated reduction in the reporter gene,
PIK3CA silencing by siRNA also decreased GLI regulatory
reporter gene activity to 44% in A549-GLI cells (Fig. 5A).
The effect of pharmacological inhibition of PI3K on the
GLI reporter gene was also examined. While SMOH inhi-
bition by cyclopamine did not affect GLI reporter gene
activity in accordance with a previous study that showed
GLI1 activation is ligand independent in A549 cells [18],
a significant decrease in activity was observed by inhibi-
tion of PI3K with LY294002 (Fig. 5B).
The results demonstrated so far, which indicate that
p70S6K2-inhibition down-regulated GLI1-mediated tran-
scription via regulation of GSK3β function, were predom-
inately investigated in A549 cells. The activation of GSK3β
and GLI1 degradation by p70S6K2-silencing was also con-
firmed in the H1915 cell line.
Discussion
A number of researchers have reported the development
of HH/GLI1 cascade inhibitors as a new class of anti-
tumor agent. For HH ligand-dependent cancers, pharma-
cological inhibition of the upstream components of the
pathway offers an effective anti-tumor action. Indeed, lig-
and neutralizing antibodies or cyclopamine (an SMOH
inhibitor) in preclinical studies have shown significant
progress in regressing tumor development [5,12]. It has
been reported, however, that GLI1 signaling is activated in
a subset of NSCLC through the mechanism of overexpres-
sion of GLI1 transcription factor with no deregulation of
PTCH or SMOH [18]. This signaling activation is ligand-
independent, given the fact that cyclopamine had little
effect on both cell growth and GLI target gene expression
in NSCLC cells. In order to suppress the HH pathway,
novel therapeutic targets to intervene in the GLI1 cascade
in NSCLC need to be identified. As kinases are widely rec-
ognized as druggable proteins which are amenable to the
development of small molecule chemical inhibitors, a
kinome-wide siRNAs screen was performed to identify
kinase regulators of the HH pathway. Unexpectedly,
silencing of p70S6K2, a key regulator of the PI3K pathway,
remarkably reduced the activity of GLI regulatory gene,
indicating that p70S6K2 may serve as a therapeutic target
to inactivate the HH cascade in cancer. The results of this
study demonstrate that p70S6K2- and GLI1-silencing
achieved similar levels of suppression of the GLI regula-
tory reporter gene. This suggests that pharmacological
inhibition of p70S6K2 would sufficiently down-regulate
the HH/GLI1 cascade in a subpopulation of NSCLCs with
GLI1 overexpression.
The cross-talk between the HH pathway and other cancer
relevant pathways has been extensively studied. Stimula-
tion of PRKCD activates ERK signaling and up-regulates
GLI transcription without the addition of an HH-ligand
[32], indicating the contribution of the PRKCD/ERK path-
way to GLI activation. Both activation and inhibition of
PRKCD by phorbol esters and pharmacological interven-
tion respectively has illustrated that PRKCD controls GLI
activation of HH signaling. The present data from the
kinome-wide siRNA screen also identified PRKCD-siRNA
as a negative regulator of the HH pathway (Table 1); sup-
porting previous evidence that PRKCD functions to con-
Inhibition of p70S6K2 causes GLI1 degradation through  reduction in phospho-GSK3β at Ser9 residue Figure 4
Inhibition of p70S6K2 causes GLI1 degradation 
through reduction in phospho-GSK3β at Ser9 resi-
due. A, Phosphorylated-GSK3β level of cells treated with 
p70S6K2 siRNA. Cell lysates were recovered and subjected 
to western blotting analysis to detect total p70S6K2, total 
GSK3β and phospho-GSK3β respectively at the indicated 
time points after siRNA transfection. B, GLI1 protein level of 
cells treated with p70S6K2-siRNA. A549 cells were also 
treated with siRNAs (control, p70S6K1, p70S6K2, and GLI1), 
and cell lysate was subjected to western blotting with GLI1, 
p70S6K1 and p70S6K2 antibodies 72 hr after transfection.
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trol the GLI1cascade. Recent advances in stem cell biology
have also presented cross-talk between the HH pathway
and other developmental pathways such as Wnt, Hox and
Notch signaling [34,35]. Examples include a study on
chronic myeloid leukemia stem cells, which showed that
HH-dependent Stat3 activation orchestrates down-regula-
tion of Hox genes such as HoxA2 and HoxB4. With respect
to the association of HH and PI3K pathways, a pioneering
study showed that PI3K itself and AKT were found to be
essential for the activation of the GLI reporter gene in
response to HH stimulus in non-tumorigenic NIH3T3
cells harboring the GLI regulatory reporter gene, the
expression of which is regulated in an HH ligand depend-
ent manner [36]. The same study also indicated that up-
regulation of the GLI reporter gene by PI3K/AKT activa-
tion is mediated by controlling PKA activity. Singh and
colleagues also reported that PI3K/AKT contributes to
activation of the HH/GLI1 signaling pathway in ALK-pos-
itive anaplastic large cell lymphoma (ALCL), but not in
ALK-negative ALCL [37]. However, the involvement of
p70S6 kinases was not investigated. The current study pro-
vides additional evidence that the PI3K pathway contrib-
utes to the activation of the GLI1 cascade in NSCLC cells.
Moreover, the mechanism relating PI3K to GLI1 regula-
tion observed in this study is novel and distinct from the
previous study in that the downstream effector of PI3K
pathway, p70S6K2, controls GLI-mediated transcription
via phosphorylating GSK3β which regulates GLI1 stabili-
zation (Fig. 6).
The kinome-wide siRNA screen of the HH signaling path-
way performed in the present study found that p70S6K2-
silencing suppresses GLI1-regulatory genes, but p70S6K1-
silencing does not. Subsequent studies also revealed that
the mechanism for down-regulation in the GLI1 cascade
is caused by p70S6K2-silencing. Recent studies have facil-
itated our understanding that p70S6K1 and p70S6K2 pos-
sess redundant and distinct functions in cell signaling
transduction [38]. An example of a commonly conserved
function is that both p70S6K1/2 kinases transduce the sig-
nal in the down stream of the PI3K/mTOR cascade to
accelerate protein biosynthesis. In the present siRNA
screen, however, p70S6K1 was not identified as a GLI1
cascade inhibitory siRNA. The result that p70S6K1-siRNA
treatment did not affect the HH/GLI1 cascade in NSCLC
cells was also carefully confirmed by independent experi-
ments which measured reduction in p70S6K1 expression
and GLI regulatory reporter gene activity (data not
GLI reporter gene activity reduction by PIK3CA-inhibition Figure 5
GLI reporter gene activity reduction by PIK3CA-inhibition. A, Effect of PI3K-silencing by siRNA on GLI regulatory 
reporter gene. GLI regulatory reporter gene activity was measured by β-lactamase assay 72 hr after siRNA transfection (PLK1, 
GLI1 and PIK3CA) into A549-GLI cells. PLK1-siRNA was treated as a negative control to confirm that cytotoxicity did not affect 
reporter activity. GLI1-siRNA was used as a positive control. B, Effect of PI3K-inhibition by LY294002 on GLI regulatory 
reporter gene. The A549-GLI cells were treated with PI3K inhibitor, LY294002 (90 μM) and SMOH inhibitor KAAD-
cyclopamine (800 nM) respectively. β-lactamase activity was measured 12 hr after treatment. Data are the mean and SD of 
three independent experiments. **, P ≤ 0.01 compared with control.
0
20
40
60
80
100
120
Control PLK1 GLI1 PIK3CA
G
L
I
R
e
p
o
r
t
e
r
 
A
c
t
i
v
i
t
y
 
(
%
)
0
20
40
60
80
100
120
Control KAAD-
Cyclopamine
LY294002
G
L
I
R
e
p
o
r
t
e
r
 
A
c
t
i
v
i
t
y
 
(
%
)
AB
siRNA





 

Molecular Cancer 2009, 8:44 http://www.molecular-cancer.com/content/8/1/44
Page 8 of 10
(page number not for citation purposes)
shown). Moreover, simultaneous double-knockdown of
p70S6K1 and p70S6K2 was investigated to examine any
synergistic effect on the inhibition of the GLI1 cascade.
This resulted in no enhancing effect on the GLI reporter
gene by p70S6K1-siRNA. This indicates that the role of
p70S6K2 in inhibiting the HH pathway may be distinct
from that of p70S6K1, although we cannot eliminate the
possibility that p70S6K1 may exert similar function in dif-
ferent types of cells. Further studies to examine expres-
sion/activation levels of p70S6K1/2 and the GLI1 cascade
in diverse types of clinical samples and cell lines would
provide some insights on this issue.
Conclusion
We report herein that p70S6K2 positively regulates GLI1-
mediated transcription through modulating GSK3β in
NCSLC. Given the recent finding that various types of
tumors have deregulations in the HH/GLI cascade inde-
pendent of the HH ligand, in which modulation of
upstream components are less effective [18], it is impera-
tive that novel therapeutic targets for the GLI1 cascade be
identified. The identification of p70S6K2 as a positive reg-
ulator of GLI-mediated transcription provides an alterna-
tive strategy for developing therapeutic agents for ligand-
independent HH/GLI-activated tumors.
Methods
Reagents
PI3K inhibitor, LY294002, and KAAD-cyclopamine were
purchased from Merck KGaA (Dharmstadt, Germany).
Cell culture reagents and media were obtained from Invit-
rogen (Carlsbad, CA).
Establishment of stable cell lines of A549 harboring GLI 
regulatory reporter gene
A549 cells were transfected with pLenti-bsd/GLI-bla vec-
tor (Invitrogen), which contains β-lactamase reporter gene
under the transcriptional control of a (8×) Gli response
element with tata-minimal promoter, by lipofection using
Lipofectamine reagent (Invitrogen). The cells transfected
with the vector were cultured with growth medium con-
taining 3.8 μg/ml of blasticidin for 14 days, and stable cell
lines were established. Several stable clones were trans-
fected with GLI1 siRNA and a few clones were identified
in which β-lactamase activity was reduced by more than
70% with GLI1-silencing.
siRNA transfection and measurement of mRNA expression
The sequence of p70S6K2 siRNA used in the present exper-
iments, other than kinome-wide siRNA screen, was
GCCUAGAGCCUGUGGGACAtt (B-bridge, Mountain
View, CA). The phenotypes observed in the p70S6K2 were
confirmed by two additional sequences, GGUGUUC-
CAGGUGCGAAAGtt (Applied Biosystems/Ambion, Aus-
tin, TX) and GCAGAGAACCGGAAGAAAAtt (B-bridge).
The following siRNAs were also used: GLI1-siRNA (M-
003896-00-0020: Thermo Fisher Scientific Inc., Waltham,
MA);  polo-like kinase 1 (PLK1)-siRNA (M-003290-01-
0010: Thermo Fisher Scientific Inc.); control-siRNA (D-
001810-01-05: Thermo Fisher Scientific Inc.); and,
human kinome siRNA set (AM80010V3, Applied Biosys-
tems/Ambion). For siRNA transfection, 900 cells were
seeded per well in 96-well plate and incubated for 24 hr.
siRNA was mixed with a lipofection reagent, siLentFect
(Bio-Rad, Hercules, CA) according to the manufacturer's
instructions, and transfected into the A549 cells. mRNA
was recovered and extracted 48 hr after transfection with
RNAeasy (Qiagen, Hilden, Germany). Reverse transcrip-
tion was performed for 500 ng of total RNA, and the
cDNA obtained was applied to TaqMan PCR for quantifi-
cation of mRNA expression. The primers and probe used
for the quantitative polymerase chain reaction (qPCR)
were:  p70S6K2  (Hs00177689-M1, Applied Biosystems,
Foster City, CA); GLI1 (Hs00171790-M1, Applied Biosys-
tems),  Cyclin D1 (Hokkaido system science, Sapporo,
Proposed model of the relationship between p70S6K2 and  the HH pathway Figure 6
Proposed model of the relationship between 
p70S6K2 and the HH pathway. The activation of the 
canonical HH pathway is initiated by binding of the HH ligand 
to its receptor PTCH, which relieves the repression of 
SMOH. The activation of SMOH is translated into GLI zinc-
finger transcription factors. Glycogen synthase kinase-3 beta 
(GSK3β) negatively regulates GLI transcription factors coop-
erating with other kinases such as PKA and CK1s. GSK3β is 
negatively regulated through phosphorylation by p70S6K2 
which is a downstream effecter of the PI3K pathway.
SMOH
HH
Transcription ON
GSK3
HH active
PTCH
GLI1
GLI1
P
p70S6K2
PI3K
pathway
Degradation
P
NSCLCMolecular Cancer 2009, 8:44 http://www.molecular-cancer.com/content/8/1/44
Page 9 of 10
(page number not for citation purposes)
Japan); and, γ-catenin (Hs00158408-M1, Applied Biosys-
tems). Data were collected and analyzed using an ABI
7900HT Fast Real-Time PCR System (Applied Biosys-
tems). The relative mRNA expression data were normal-
ized to β-actin expression, measured with pre-designed
qPCR primers and probe (4310881E, Applied Biosys-
tems).
Cell viability assay and β-lactamase assay
Cell viability was measured by CellTiter-Glo Luminescent
Cell Viability Assay (Promega, Madison, WI), 72 or 96 hr
after siRNA transfection. An equal volume (100 μL) of
CellTiter-Glo Reagent was added to medium, and mixed
gently for 2 min on an orbital shaker. The solution was
incubated at room temperature for 10 min to allow it to
stabilize and luminescence to appear, after which the
luminescence was measured. The activity of β-lactamase
was quantified with GeneBLAzer™ Detection Kits (Invitro-
gen) according to the manufacturer's instructions. A 6 ×
substrate loading solution was added to the cells to 1 ×
final concentration and the cells in the buffer were incu-
bated for 6 hr. β-lactamase activity was then measured
using a fluorescent plate reader. The β-lactamase activity
was normalized to cell number, measured by CellTiterGlo
Luminescent Cell Viability Assay (Promega).
Immunoblotting
For immunoblotting of total and phosphorylated GSK3β
and GLI1, cell lysate was extracted from A549 or H1915
cells with a lysis buffer (50 mM HEPES, 250 mM NaCl,
0.1% NP-40, 0.1 mM DTT) comprising a 1:00 dilution of
protease inhibitor cocktail (Thermo Fisher Scientific Inc.
Rockford, IL) containing AEBSF, Aprotinin, Bestatin, E-64,
Leupeptin, Pepstatin A), and a 1:00 dilution of phos-
phatase inhibitor cocktail (Thermo Fisher Scientific Inc.)
containing sodium fluoride, sodium orthovanadate,
sodium pyrophosphate and β-glycerophosphate. The
extracted 20 μg of total protein was subjected to 10% SDS-
PAGE analysis. Proteins were visualized by ECL chemilu-
minescence reagents (GE Healthcare UK Ltd., Bucking-
hamshire, UK) using primary antibodies specific to total
GSK3β (#9315, Cell Signaling Technology, Danvers, MA),
phosphorylated GSK3β at Ser9 residue (#9336, Cell Sign-
aling Technology) and GLI1 (#2553, Cell Signaling Tech-
nology), p70S6K1 (#9202, Cell Signaling Technology)
and p70S6K2 (sc-9379, Santa Cruz Biotechnology, Santa
Cruz, CA).
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